Alnylam, First Human Proof of Concept for an RNAi Therapeutic with GEMINI Study

Feb 29, 2008 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced that it has achieved human proof of concept with an RNAi therapeutic, a first for the industry. Results from the company's GEMINI trial with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV), showed statistically significant anti-viral efficacy. In the Phase II experimental infection study, treatment with ALN-RSV01 led to a decreased RSV infection rate, an increase in the number of subjects who remained free of infection, and was safe and well tolerated. Results from GEMINI are being presented at the International Symposium on Respiratory Viral Infections in Singapore... Alnylam's Press Release -